Jean Jacques Bienaime

Filings by Jean Jacques Bienaime span 5 companies, the busiest being Biomarin Pharmaceutical Inc, Immunome Inc. and Incyte Corp. We count 80 filings; the first trade dates from 30 April 2021 and the latest from 17 August 2026.

In open-market terms, that means 21 purchases worth €1.1M on one side and 14 sales worth €2.0M on the other. No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 19 share grants and 18 option exercises. In 2026 alone, the filings show 16 purchases and 2 sales.

In size, the median ticket on the buying side is €40k. Measured against the company's value, the median purchase equals 0.0034% of market capitalisation, across 8 purchases where it is known. Of 21 purchases, 6 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The latest filing, published on 19 August 2026, reports an open-market purchase of €8,866 in Keros Therapeutics, Inc. Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.